Literature DB >> 26430910

Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.

Grzegorz Helbig1, Anna Soja1, Alina Świderska2, Marek Hus3, Sławomira Kyrcz-Krzemień1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26430910     DOI: 10.3109/10428194.2015.1065983

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  3 in total

1.  Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.

Authors:  Georgia Metzgeroth; Juliana Schwaab; Nicole Naumann; Mohamad Jawhar; Torsten Haferlach; Alice Fabarius; Andreas Hochhaus; Wolf-Karsten Hofmann; Nicholas C P Cross; Andreas Reiter
Journal:  Blood Adv       Date:  2020-02-11

Review 2.  Treatment-free remission in patients with chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Nat Rev Clin Oncol       Date:  2020-05-06       Impact factor: 66.675

3.  Clinical and Biological Markers in Hypereosinophilic Syndromes.

Authors:  Paneez Khoury; Michelle Makiya; Amy D Klion
Journal:  Front Med (Lausanne)       Date:  2017-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.